Trials / Active Not Recruiting
Active Not RecruitingNCT04707326
Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study.
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,040 (actual)
- Sponsor
- Erasmus Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to determine real-life clinical efficacy of virally suppressed patienst switching to DTG/3TC compared to DTG triple drug cART controls
Detailed description
Dolutegravir (DTG) based dual antiretroviral therapy constitutes a paradigm shift from triple drug based therapy. Data outside clinical trials are scarce. This study evaluates the value of DTG/3TC in real life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dolutegravir / Lamivudine Pill | HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2023-11-01
- Completion
- 2026-11-01
- First posted
- 2021-01-13
- Last updated
- 2024-12-20
- Results posted
- 2024-12-20
Locations
9 sites across 1 country: Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04707326. Inclusion in this directory is not an endorsement.